Crescent Biopharma (CBIO) Liabilities and Shareholders Equity (2013 - 2026)
Crescent Biopharma (CBIO) reported Liabilities and Shareholders Equity of $199.1 million for Q1 2026, up 3223.16% year-over-year from $6.0 million in Q1 2025, and down 17.13% on a QoQ basis from $240.3 million in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $199.1 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 3223.16% year-over-year to $199.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $735.1 million (up 799.5% YoY) and the FY2025 annual result came in at $240.3 million, up 574.66% from the prior year.
- Liabilities and Shareholders Equity declined to $199.1 million in Q1 2026 per CBIO's latest filing, from $240.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $240.3 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $56.0 million (2022), against an average of $78.5 million.
- The widest annual swing landed in 2025, when Liabilities and Shareholders Equity tumbled 82.48%; it then jumped 3223.16% in 2026.
- Tracing CBIO's Liabilities and Shareholders Equity over 5 years: stood at $51.8 million in 2022, then retreated by 12.53% to $45.3 million in 2023, then dropped by 21.4% to $35.6 million in 2024, then soared by 574.66% to $240.3 million in 2025, then decreased by 17.13% to $199.1 million in 2026.
- Per Business Quant, the three latest CBIO Liabilities and Shareholders Equity figures stand at $199.1 million (Q1 2026), $240.3 million (Q4 2025), and $138.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 199.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199.13 Mn |
| Dec 31, 2025 | 240.29 Mn |
| Sep 30, 2025 | 138.27 Mn |
| Jun 30, 2025 | 157.43 Mn |
| Mar 31, 2025 | 5.99 Mn |
| Dec 31, 2024 | 35.62 Mn |
| Sep 30, 2024 | 15.70 Mn |
| Jun 30, 2024 | 24.42 Mn |
| Mar 31, 2024 | 34.20 Mn |
| Dec 31, 2023 | 45.32 Mn |
| Sep 30, 2023 | 53.20 Mn |
| Jun 30, 2023 | 61.82 Mn |
| Mar 31, 2023 | 68.92 Mn |
| Dec 31, 2022 | 51.81 Mn |
| Sep 30, 2022 | 55.96 Mn |
| Jun 30, 2022 | 65.04 Mn |
| Mar 31, 2022 | 81.46 Mn |
| Dec 31, 2021 | 94.35 Mn |
| Sep 30, 2021 | 107.94 Mn |
| Jun 30, 2021 | 124.38 Mn |
| Mar 31, 2021 | 138.02 Mn |
| Dec 31, 2020 | 142.83 Mn |
| Sep 30, 2020 | 150.42 Mn |
| Jun 30, 2020 | 158.35 Mn |
| Mar 31, 2020 | 162.10 Mn |
| Dec 31, 2019 | 167.97 Mn |
| Sep 30, 2019 | 180.45 Mn |
| Jun 30, 2019 | 192.33 Mn |
| Mar 31, 2019 | 204.44 Mn |
| Dec 31, 2018 | 214.84 Mn |
| Sep 30, 2018 | 225.17 Mn |
| Jun 30, 2018 | 235.70 Mn |
| Mar 31, 2018 | 247.42 Mn |
| Dec 31, 2017 | 128.58 Mn |
| Sep 30, 2017 | 115.82 Mn |
| Jun 30, 2017 | 121.62 Mn |
| Mar 31, 2017 | 37.17 Mn |
| Dec 31, 2016 | 42.39 Mn |
| Sep 30, 2016 | 48.01 Mn |
| Jun 30, 2016 | 55.77 Mn |
| Mar 31, 2016 | 40.70 Mn |
| Dec 31, 2015 | 48.46 Mn |
| Sep 30, 2015 | 55.74 Mn |
| Jun 30, 2015 | 62.04 Mn |
| Mar 31, 2015 | 48.46 Mn |
| Dec 31, 2014 | 57.26 Mn |
| Sep 30, 2014 | 62.43 Mn |
| Jun 30, 2014 | 67.52 Mn |
| Mar 31, 2014 | 58.06 Mn |
| Dec 31, 2013 | 5.28 Mn |